Trust signals
Key Takeaways
- Bacteriostatic water for injection (0.9% benzyl alcohol) is the preferred diluent for multi-dose vials because benzyl alcohol is bacteriostatic, not bactericidal, and buys time against contamination between draws.
- A 1 mg/mL target concentration is practical: 5 mg of lyophilized semaglutide into 5 mL of bacteriostatic water gives 0.25 mL per 0.25 mg dose on a standard insulin syringe.
- Ozempic is pre-formulated and requires zero reconstitution. Any semaglutide that requires dilution is either a compounded preparation or a research-use lyophilized peptide, and those carry different (and often less validated) stability data.
- Never shake or vortex the vial. Mechanical agitation promotes aggregation of peptide chains, creating particles that reduce bioavailability and can trigger injection-site reactions.
- Reconstituted solutions should be clear, colorless to pale yellow, and free of particles. Discard any vial with cloudiness, visible flakes, or discoloration before it reaches a syringe.
How do you dilute semaglutide? (Direct answer, 40-60 words)
How to dilute semaglutide: inject bacteriostatic water for injection slowly along the inner wall of the vial containing lyophilized semaglutide, targeting 1 to 2 mg/mL concentration. Swirl gently until fully dissolved. Do not shake. Store refrigerated at 2 to 8 degrees C and use within the window your compounding pharmacy specifies, typically 28 to 30 days.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What diluent should I use to reconstitute semaglutide?
- What concentration should I mix semaglutide to?
- Step-by-step: how do you actually dilute semaglutide?
- How do I calculate the injection volume after diluting?
- How long is reconstituted semaglutide stable?
- What most pages get wrong about diluting semaglutide
- Why does diluent chemistry matter? The degradation science
- Evidence ledger: what the data actually supports
- Head-to-head: compounded reconstituted vs. Ozempic pen
- Label and COA literacy: how to judge what you have
- FAQ
- Sources
- Footer disclaimers
What diluent should I use to reconstitute semaglutide?
The two options in practice are bacteriostatic water for injection (BWI) and sterile water for injection (SWI).
| Diluent | Preservative | Multi-dose safe? | Best used when |
|---|---|---|---|
| Bacteriostatic water for injection (BWI) | 0.9% benzyl alcohol | Yes, within labeled window | Multi-draw vials stored up to 28 to 30 days |
| Sterile water for injection (SWI) | None | No | Single-dose-only preparation, discard after one draw |
| Normal saline (0.9% NaCl) | None | No | Single-dose only; adds sodium chloride which is generally compatible but adds no benefit over SWI |
BWI is the practical standard because most research and compounding protocols require multiple draws from one vial over several weeks. The benzyl alcohol inhibits microbial growth between uses. It does not sterilize a contaminated vial, so aseptic technique is still mandatory.
What concentration should I mix semaglutide to?
There is no single universal standard. Practical targets used in compounding and research settings range from 0.5 mg/mL to 2 mg/mL. The tradeoffs:
- 0.5 mg/mL: larger injection volumes per dose (0.5 mL for a 0.25 mg dose). More forgiving for dose titration math on small doses, but more liquid per injection.
- 1 mg/mL: the most common working concentration. 0.25 mL delivers 0.25 mg; 0.5 mL delivers 0.5 mg. Maps cleanly onto insulin syringe markings.
- 2 mg/mL: smaller injection volumes, useful for larger doses (1 mg in 0.5 mL). Increases the precision demand on small volumes; a 10% measurement error at 0.125 mL is a larger absolute dose error than the same error at 0.25 mL.
For a practical 1 mg/mL reconstitution with a 5 mg vial: draw 5 mL of BWI into a syringe and inject it slowly into the powder vial. Label the vial with date, concentration, and diluent.
Step-by-step: how do you actually dilute semaglutide?
- Gather materials: lyophilized semaglutide vial, bacteriostatic water for injection, a 3 to 5 mL syringe with a 23-gauge needle for reconstitution, insulin syringes for dosing, 70% isopropyl alcohol swabs, a clean surface.
- Check the powder: the lyophilized cake should appear white to off-white, intact or slightly crumbled. Any unusual color or visible moisture indicates a problem before you start.
- Wipe both septa: swab the top of the BWI vial and the peptide vial with a fresh alcohol swab. Allow each to air-dry for 30 seconds. Wet alcohol on the needle carries the alcohol into the vial and can degrade the peptide.
- Draw the BWI: insert the reconstitution needle into the BWI vial and withdraw your calculated volume (e.g., 5 mL for 1 mg/mL from a 5 mg vial).
- Add the diluent slowly: insert the needle into the peptide vial and aim the stream of BWI at the inside glass wall, not directly at the lyophilized cake. This minimizes mechanical disruption of the peptide.
- Swirl gently: rotate the vial in your palm with slow circular motions for 30 to 60 seconds. Do not shake or vortex. The solution should become clear. If particulate remains after 2 minutes of gentle swirling, do not use the vial.
- Inspect: hold the vial up to light. The solution must be clear and essentially colorless to very pale yellow with no visible particles before any draw.
- Label and store: write the preparation date, concentration (mg/mL), and discard date on the vial. Refrigerate at 2 to 8 degrees C. Do not freeze.
How do I calculate the injection volume after diluting semaglutide?
The formula is straightforward:
Injection volume (mL) = Desired dose (mg) divided by Concentration (mg/mL)
| Concentration (mg/mL) | Desired dose (mg) | Draw this volume (mL) | On a 1 mL insulin syringe (100-unit) |
|---|---|---|---|
| 0.5 | 0.25 | 0.5 mL | 50 units |
| 1.0 | 0.25 | 0.25 mL | 25 units |
| 1.0 | 0.5 | 0.5 mL | 50 units |
| 1.0 | 1.0 | 1.0 mL | 100 units (full syringe) |
| 2.0 | 0.25 | 0.125 mL | 12.5 units (harder to measure accurately) |
| 2.0 | 0.5 | 0.25 mL | 25 units |
The insulin syringe "unit" convention: a 100-unit (1 mL) insulin syringe has 100 graduation marks. Each mark equals 0.01 mL. 25 units on that syringe equals 0.25 mL. This is not insulin units; it is just a volume marking.
How long is reconstituted semaglutide stable?
There are two distinct situations and they should not be conflated:
Ozempic (commercial solution): the FDA-approved labeling states the pen may be stored at room temperature (up to 30 degrees C) or refrigerated for up to 56 days after first use. This stability is supported by pharmaceutical-grade formulation data with specific buffers, a preservative (phenol), and the exact salt form (semaglutide as the free base).
Compounded or research lyophilized semaglutide reconstituted with BWI: no equivalent published stability dataset exists for most extemporaneous preparations. Compounding pharmacies typically recommend use within 28 to 30 days under refrigeration, following general peptide compounding conventions. This is a conservative professional standard, not an independently validated stability claim for every specific formulation.
What most pages get wrong about diluting semaglutide
This is the section commodity blogs skip entirely.
1. Salt form matters and most sources ignore it. Compounded semaglutide is often supplied as semaglutide acetate or semaglutide sodium rather than the free base used in Ozempic. The molecular weight differs slightly (acetate counter-ion adds roughly 60 g/mol to the MW). A vial labeled "5 mg semaglutide acetate" contains slightly less active peptide by mass than "5 mg semaglutide base." Some compounding suppliers account for this; others do not label clearly. Check whether the COA specifies the salt form and whether the stated purity is calculated on the free base or the salt. If you cannot confirm this, your stated dose may be off by a few percent.
2. BWI does not sterilize your vial. Benzyl alcohol at 0.9% inhibits bacterial growth over time; it does not kill a contamination event from poor aseptic technique. If you introduce a contaminant during reconstitution, benzyl alcohol only slows, not stops, the problem. Every commodity page says "use bacteriostatic water" without explaining this limit.
3. Purity on a COA does not equal potency. A certificate of analysis may show 98% purity by HPLC, but HPLC purity measures the peptide peak relative to detected impurities, not absolute mass. It does not confirm endotoxin content, sterility, or correct peptide sequence. A research-grade peptide with 98% HPLC purity and no endotoxin testing is not the same risk profile as a pharmacy-compounded preparation tested per USP 85 (bacterial endotoxins).
4. The reconstitution needle gauge matters. Using a fine (29 to 31 gauge) needle to inject diluent into the vial creates high-velocity streams that can shear and aggregate the peptide. Use a 23 to 25 gauge needle for reconstitution, then switch to a fine insulin needle for injection draws.
Why does diluent chemistry matter? The degradation science
Semaglutide is a 31-amino-acid GLP-1 analogue with a C18 fatty diacid chain attached via a linker at lysine-26. The peptide backbone is susceptible to two main degradation routes in solution:
Hydrolysis: water attacks peptide bonds, especially at aspartate-proline sequences and at the ester or amide bonds of the fatty acid linker. The rate is pH-dependent and accelerated at both extremes. Near-neutral to mildly acidic pH (roughly 5 to 7) slows hydrolysis. BWI typically falls in this range. Strongly alkaline conditions (pH greater than 8) or acidic conditions (pH less than 4) accelerate hydrolysis meaningfully.
Aggregation: the hydrophobic fatty acid chain that makes semaglutide albumin-binding also promotes peptide-peptide clustering when the peptide is mechanically agitated, exposed to air-water interfaces, or stored at elevated temperatures. Aggregated peptide forms visible particles and loses receptor-binding activity. This is why shaking is prohibited and why freeze-thaw cycles are harmful: ice crystal formation creates interfaces that nucleate aggregation.
Bacteriostatic water's benzyl alcohol does not directly protect against either of these routes. Its role is purely antimicrobial. Proper pH, cold temperature, and gentle handling are the real stability controls.
Evidence ledger: what the data actually supports
| Claim | Best evidence type | Effect direction | Confidence |
|---|---|---|---|
| BWI inhibits microbial growth in multi-dose vials | USP and pharmacopeial benzyl alcohol preservative standards; well-established pharmaceutical chemistry | Supportive | High |
| Ozempic stable 56 days after first use at up to 30 degrees C | FDA-approved labeling backed by Novo Nordisk stability data | Established for that specific formulation | High (for Ozempic only) |
| Reconstituted compounded semaglutide stable 28 to 30 days refrigerated | Compounding pharmacy convention; no published peer-reviewed stability kinetic data identified for extemporaneous BWI reconstitution | Conservative assumption, not independently validated | Low to Moderate |
| Agitation causes peptide aggregation | General peptide formulation science; documented for GLP-1 class peptides in formulation literature | Causal (agitation increases aggregation) | Moderate to High (class-level; semaglutide-specific published agitation studies not identified) |
| Salt form (acetate vs. free base) affects nominal dose calculation | Basic pharmaceutical chemistry; MW difference is calculable | Quantitative effect, typically a few percent | High (chemistry fact); clinical significance at typical doses: Low |
| Subcutaneous bioavailability of compounded semaglutide equals Ozempic | No published human PK comparison identified for extemporaneously reconstituted lyophilized semaglutide vs. Ozempic | Assumed equivalent by practitioners; not formally demonstrated | Very Low |
Head-to-head: reconstituted compounded semaglutide vs. Ozempic pen
| Factor | Compounded reconstituted semaglutide | Ozempic pen (FDA-approved) |
|---|---|---|
| Requires dilution by user? | Yes | No, pre-formulated |
| Formulation stability data | Not independently published for most preparations | Full pharmaceutical stability package, FDA reviewed |
| Salt form certainty | Varies by supplier; check COA | Free base, specified in labeling |
| Preservative | Benzyl alcohol (from BWI) if used correctly | Phenol (pharmaceutical grade, specified concentration) |
| Endotoxin testing | Required by USP 797 for sterile compounded preps; not guaranteed for research-grade peptide | Performed per pharmaceutical manufacturing standards |
| Dose accuracy | Dependent on user math and technique | Fixed pen dial settings; validated delivery |
| Regulatory status (US) | Compounded: legal under certain conditions per FDA 503A/503B. Research peptide: not for human use | FDA-approved prescription medication |
| Where compounded semaglutide loses | Sterility assurance, formulation validation, dose precision, regulatory clarity | N/A |
| Where compounded may differ | Dose flexibility, cost in some markets | Fixed dose steps |
The honest judgment: for any patient with access to a prescription for FDA-approved semaglutide, the pre-formulated pen eliminates the reconstitution risk profile entirely. Compounded reconstituted semaglutide involves user-introduced variability at every step listed above.
Label and COA literacy: how to judge what you have
Before you dilute anything, read what you actually have.
What to look for on a COA:
- Molecular identity: the COA should confirm the peptide sequence or CAS number for semaglutide (910463-68-6). If only a generic "GLP-1 analogue" or trade name appears without a CAS or sequence confirmation, the identity is unverified.
- Salt form: the label should state whether this is semaglutide acetate, semaglutide sodium, or the free base. If absent, ask the supplier before reconstituting.
- Purity method: "98% purity" means little without knowing the method (HPLC, mass spec) and what was measured. Reversed-phase HPLC purity at a single wavelength does not detect all possible impurities or confirm sequence fidelity. Mass spectrometry confirmation is a higher standard.
- Endotoxin: for any preparation intended for injection, look for "endotoxin tested" with a result in EU/mg. USP 85 compliance is the relevant standard for pharmacy compounding. Research peptides from non-pharmacy sources frequently lack this test.
- Sterility: lyophilized peptides are not always sterile. A COA showing purity does not imply sterility. Compounding pharmacies test per USP 71. Research suppliers generally do not.
- Stated vial fill weight: confirm the stated mg per vial matches your dilution math before drawing.
What a degraded reconstituted vial looks like: cloudiness, white or off-white particulate matter, any visible flake or strand, yellow-brown color beyond a very faint pale yellow. A properly reconstituted solution is water-clear.
FAQ
How do you dilute semaglutide powder for injection?
Add bacteriostatic water slowly along the inner vial wall, not directly onto the lyophilized cake. Swirl gently until dissolved. Do not shake or vortex. Calculate volume based on your target concentration before drawing any dose.
What diluent should I use to reconstitute semaglutide?
Bacteriostatic water for injection (0.9% benzyl alcohol) is the standard for multi-dose vials. Sterile water for injection is acceptable only for single-dose, single-draw preparations. Normal saline works chemically but also lacks preservative and should be treated as single-dose only.
What concentration should I mix semaglutide to?
1 mg/mL is the most practical working concentration. It maps cleanly to insulin syringe markings (0.25 mL per 0.25 mg dose) and keeps measurement error manageable. Concentrations above 2 mg/mL are rarely necessary and make small-dose measurements harder to be precise about.
How long is reconstituted semaglutide stable?
Ozempic (the commercial product) is labeled stable 56 days after first use. Extemporaneously reconstituted compounded preparations do not carry equivalent validated stability data. The compounding pharmacy convention of 28 to 30 days refrigerated is conservative and reasonable, but not independently verified for every formulation.
Can I use normal saline instead of bacteriostatic water?
Yes, with a critical caveat: saline has no preservative. Treat any saline-reconstituted vial as a single-use preparation and discard it immediately after one draw. Do not store a saline-reconstituted vial for later use.
What does degraded or improperly diluted semaglutide look like?
Cloudiness, visible particles, or yellow-brown discoloration beyond a very faint pale tint indicate degradation or contamination. A properly reconstituted solution is clear and essentially colorless to very pale yellow. Discard any questionable vial without using it.
How do I calculate the injection volume after diluting semaglutide?
Injection volume (mL) equals desired dose (mg) divided by concentration (mg/mL). At 1 mg/mL: 0.25 mg requires 0.25 mL; 0.5 mg requires 0.5 mL. At 2 mg/mL: 0.25 mg requires 0.125 mL. Confirm your concentration label before every calculation.
Does the pH of the diluent matter for semaglutide stability?
Yes. Peptide hydrolysis accelerates at pH extremes. Bacteriostatic water typically sits near pH 5 to 7, which is appropriate. Avoid mixing semaglutide with alkaline solutions or strongly acidic diluents, as either condition accelerates peptide bond breakdown.
Can you freeze reconstituted semaglutide?
Do not freeze reconstituted solutions. Freeze-thaw cycles create ice crystal interfaces that promote peptide aggregation and reduce potency. The lyophilized powder handles freezing well; the reconstituted solution does not. Store reconstituted vials at 2 to 8 degrees C only.
Is diluting semaglutide at home safe?
Reconstitution outside a pharmacy clean room cannot achieve the same sterility assurance as a licensed facility using laminar flow, endotoxin-tested materials, and validated technique. This is one reason regulatory agencies require sterile compounding in licensed settings. The risk is real and should not be dismissed.
What syringe and needle should I use to draw diluted semaglutide?
Use a 1 mL insulin syringe (28 to 31 gauge) for subcutaneous injection. Use a larger gauge (23 to 25) for reconstitution only, then switch needles. Wipe the septum with 70% isopropyl alcohol and let it dry completely before each draw. Use a fresh needle for every injection.
How is compounded semaglutide different from Ozempic in terms of dilution?
Ozempic arrives as a pre-buffered, pre-formulated solution in a pen device. No user reconstitution is needed or appropriate. Compounded semaglutide (typically lyophilized, often as an acetate or sodium salt) requires user reconstitution, introduces variability, and lacks the pharmaceutical-grade stability data underpinning Ozempic's labeled storage conditions.
Sources
- FDA. Ozempic (semaglutide) injection prescribing information. Novo Nordisk. Current labeling available via FDA.gov Drugs@FDA database.
- FDA. Wegovy (semaglutide) injection prescribing information. Novo Nordisk. Current labeling available via FDA.gov Drugs@FDA database.
- United States Pharmacopeia. USP 797: Pharmaceutical Compounding, Sterile Preparations. USP-NF. Rockville, MD.
- United States Pharmacopeia. USP 85: Bacterial Endotoxins Test. USP-NF. Rockville, MD.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research. 2010;27(4):544-575. (General peptide/protein aggregation and degradation mechanisms.)
- Lau J, Bloch P, Schaffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015;58(18):7370-7380. (Semaglutide structure, lysine-26 fatty acid attachment, half-life basis.)
- FDA. FDA's Policy on Compounding of Certain Drug Products Under Sections 503A and 503B of the FD&C Act. Guidance documents available via FDA.gov.
- Bhatt DL, Mehta C. Adaptive designs for clinical trials. New England Journal of Medicine. 2016 (cited for general clinical trial methodology context, not semaglutide-specific). Note: semaglutide clinical outcomes data (SUSTAIN, STEP trial programs) published in NEJM 2016 to 2021 by Marso, Wilding et al.; those trials do not address reconstitution but establish the molecule's clinical profile.
Footer Disclaimers
Platform: FormBlends provides educational reference content. Nothing on this page constitutes medical advice, a prescription, or a recommendation to self-administer any medication.
Research Compound or Compounded Medication: Semaglutide requiring reconstitution is either a research compound not approved for human use or a compounded preparation regulated under applicable pharmacy law. It is distinct from FDA-approved Ozempic and Wegovy. Regulations governing access, prescribing, and dispensing vary by jurisdiction.
Results: Individual outcomes vary. No specific weight loss or clinical outcome is guaranteed by any reconstitution protocol.
Trademark: Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends has no affiliation with Novo Nordisk.